Triumvira Immunologics

Risk score

57

Headquarters

Flag of United States of AmericaUnited States of America

Triumvira Immunologics, Inc. (referred to as "Triumvira") was established in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co. It is an immunotherapy company aiming to develop innovative T cell therapies with improved safety and effectiveness compared to current cancer treatments, such as chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. The company's exclusive T cell Antigen Coupler (TAC) technology enlists the complete natural T cell receptor and operates independently from the major histocompatibility complex (MHC).